Abstract:This study examines the pivotal role of the PD‐1/PD‐L1 immune checkpoint interaction in tumor immunotherapy. Due to the absence of mature small molecule inhibitors in the market, exploring novel PD‐L1 small molecule inhibitors is imperative. Utilizing asymmetric biphenyl compounds developed by BMS Corporation, we assembled 39 small molecule compounds with analogous biphenyl scaffolds from the literature. By employing QSAR methods, these compounds were randomly divided into training and test sets, facilitating the successful construction of CoMFA and CoMSIA models, and thereby laying the groundwork for further research. Extracting insights from the spatial fields depicted in the three‐dimensional contour maps, including the electrostatic field, hydrophobic field, and hydrogen bond donor field, the most active molecule, 37, was selected from the training set. Its specific positions were modified, and functional groups were added to enhance its activity. Based on this, a series of structurally novel and potentially active small molecule compounds (37 a–37 e) were designed. Comprehensive studies were conducted on one of these compounds, 37 c, including molecular docking, molecular dynamics simulations, ADME predictions, and other operations, confirming its closer interaction with the amino acid residues of the PD‐L1 dimer in comparison to 37. This study offers new insights and options for the development of PD‐L1‐based small molecule inhibitors through the application of computational techniques and rational drug design principles. Blocking the interaction between programmed cell death‐1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1) is a crucial immunotherapeutic strategy for cancer. Currently, all inhibitors available on the market that target PD‐1/PD‐L1 are monoclonal antibodies, with no small molecule drugs yet accessible. This study focused on PD‐L1 and conducted three‐dimensional quantitative structure‐activity relationship (3D‐QSAR) research on 39 PD‐L1 inhibitors using Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA). The CoMFA (q2=0.593, r2=0.991) and CoMSIA (q2=0.542, r2=0.971) models were successfully established. Based on these models, a series of structurally novel and potentially active PD‐L1 inhibitors (37 a–37 e) were designed. Among these compounds, 37 c exhibited superior performance, with CoMFA predicting a pIC50 value of 9.204 and CoMSIA predicting a pIC50 value of 8.597. Further molecular docking and molecular dynamics simulations revealed that compound 37 c establishes hydrophobic interactions with BTyr56 and BVal68 of PD‐L1, engages in hydrogen bonds with AAsp122, ALys124, and BTyr123, and forms electrostatic interactions with ALys124 and AMet115. The design of this biphenyl series of inhibitors offers additional options for the development of small molecule inhibitors targeting PD‐L1, with 37 c expected to be a promising inhibitor of PD‐L1.

Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction

Identification of the FDA‐Approved Drug Pyrvinium as a Small‐Molecule Inhibitor of the PD‐1/PD‐L1 Interaction

Synthesis and preliminary evaluation of aminophenol derivatives as molecular glues blocking PD-1/PD-L1 interaction

Design, Synthesis and Biological Evaluation of Biphenyl-1,2,3-Triazole Hybrid Analogues as PD-1/PD-L1 Inhibitors

Discovery of Quinazoline Derivatives As Novel Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) Interaction.

Synthesis and Evaluation of Biphenyl-1,2,3-Triazol-Benzonitrile Derivatives as PD-1/PD-L1 Inhibitors

Rational Development of Molecularly Imprinted Nanoparticles for Blocking PD-1/PD-L1 Axis

Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1/PD-l1 interaction

Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage

Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors

Discovery of [1,2,4]Triazolo[4,3-A]pyridines As Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Discovery of Phenyl-Linked Symmetric Small Molecules As Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.

Antioxidant Properties and Aldehyde Reactivity of PD-L1 Targeted Aryl-Pyrazolone Anticancer Agents

Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents

Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction

Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2'-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors

Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction

Discovery of bioactive natural products of microbial origin as inhibitors of the PD-1/PD-L1 protein-protein interaction

Discovery of Pyrrole-imidazole Polyamides as PD-L1 Expression Inhibitors and Their Anticancer Activity via Immune and Nonimmune Pathways

Design of Biphenyl‐Type Programmed Cell Death‐Ligand 1 Inhibitors Using 3D‐QSAR, Molecular Docking, and Molecular Dynamics Simulation